Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720664 · ClinicalTrials.gov registry record · Phase 2
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04720664 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 11 participants.
The verdict
NCT04720664, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine efficacy, defined as the objective response rate (ORR) of this investigational treatment. It is hypothesized that SM-88 used with MPS will lead to significant anti-tumor responses with acceptable toxicities in patients with metastatic HR+/HER2- breast cancer.
Interventions
- DRUG SM-88
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720664
The ClinicalTrials.gov registry entry for NCT04720664 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SM-88 is the first listed.
NCT04720664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04720664 about?
NCT04720664 is a clinical study titled "Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer". This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine efficacy, defined as the objective response rate (ORR) of this investigational treatment. It is hypothesized that SM-88 us...
What is the current status of trial NCT04720664?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2021-09-22. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT04720664?
The interventions under investigation include: SM-88 (DRUG).
Who is sponsoring clinical trial NCT04720664?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.